<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258371</url>
  </required_header>
  <id_info>
    <org_study_id>DAPA-SWEET (18-5597)</org_study_id>
    <nct_id>NCT04258371</nct_id>
  </id_info>
  <brief_title>DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk</brief_title>
  <acronym>DAPA-SWEET</acronym>
  <official_title>DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MOUNT SINAI HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function,
      renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in
      patients with T2D at high cardiovascular risk and non-T2D patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In light of EMPA-REG OUTCOME, CANVAS Program and DECLARE trials, we aim to elucidate the
      impact of SGLT2 inhibition on peripheral vascular function while also exploring the effects
      of this therapy on renal function, fluid volume, neurohormonal activation and
      inflammatory/fibrotic pathways in patients with T2D at high cardiovascular risk to best
      replicate the patient populations in recent cardiovascular outcome trials (CVOT), who are
      also participating in ongoing CVOTs such as VERTIS (ertugliflozin), as well as non-T2D
      patients in other ongoing trials examining cardiorenal effects of these therapies. We will
      test the hypothesis that in a high- risk population, regardless of T2D status, SGLT2
      inhibition will improve markers of arterial stiffness (decreases in pulse wave velocity and
      augmentation index) in the study cohort - a surrogate marker of cardiovascular risk
      independent of glucose lowering. In addition, dapagliflozin will improve endothelial function
      (&quot;flow-mediated vasodilatation&quot; - FMD) and increase natriuresis (fractional excretion of
      sodium or FENa+), thereby reducing blood pressure, without inducing renal vasoconstriction or
      activation of the sympathetic nervous system (SNS). Based on extensive experimental
      literature, we also hypothesize that SGLT2 inhibition will suppress levels of
      pro-inflammatory/fibrotic mediators (see below) that have been linked with progression of
      cardiovascular and renal disease. The systematic understanding of the effects of SGLT2
      inhibitors in the setting of patients at high cardiovascular risk will enable the design of
      rational physiology-based strategies to decrease the burden of cardiorenal disease, which
      could have important clinical and research implications. Data from DAPA-SWEET will also be
      valuable to better understand the results of trials that include patients using SGLT2
      inhibitors as primary prevention strategies, such as in DECLARE TIMI-58.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to 10mg PO dapagliflozin daily or matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Acute (1 week)</time_frame>
    <description>Measured using a Sphygmocor device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>Chronic (12 weeks)</time_frame>
    <description>Measured using a Sphygmocor device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>Glomerular Filtration Rate (GFR, based on plasma iohexol clearance) will be measured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow mediated dilation</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>FMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitroglycerin mediated dilation</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Changes to systolic and diastolic function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Invasive Cardiac Output Monitoring (Measured using a NICOM device)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Cardiac output and systemic vascular resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioimpedence spectroscopy</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measure of extracellular water</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of natriuretic peptides</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of the renin-angiotensin aldosterone system (RAAS) hormones</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nitric oxide</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional excretion of sodium, using lithium clearance as a surrogate for proximal tubular sodium handling</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary concentration of the renin-angiotensin aldosterone system (RAAS) markers</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary adenosine</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of monocyte chemoattractant protein-1(MCP-1)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of intercellular adhesion molecule-1(ICAM-1)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of plasminogen activator inhibitor-1(PAI-1)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of transforming growth factor-beta (TGF-beta)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of connective tissue growth factor (CTGF)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of interleukins (IL-1beta, IL-6)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of tumour necrosis factor-alpha (TNF-alpha)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of matrix metalloproteinases 2 (MMP2)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of matrix metalloproteinases 9 (MMP9)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of advances glycation end-product (AGE)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRNA expression of receptor for AGE (RAGE)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Measured in urine and skin biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary thiobarbituric acid reactive substances (TBARS)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary 8-hydroxydeoxyguanosine (8-OHdG)</measure>
    <time_frame>Outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of hypoglycaemic episodes</measure>
    <time_frame>Throughout study completion, an average of 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Throughout study completion, an average of 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Drug related adverse events</measure>
    <time_frame>Throughout study completion, an average of 12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Matching Dapagliflozin Tablet for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks</description>
    <arm_group_label>Dapagliflozin Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo once daily for 12 weeks</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. eGFR â‰¥30 ml/min/1.73m2

          2. In patients with type 2 diabetes, HbA1c &lt;12.0%

          3. Body Mass Index (BMI) 18.5-45.0 kg/m2

          4. Blood pressure &lt; or = 160/100 at screening (sitting)

          5. Stable dose of maximally tolerated ACE inhibitor, angiotensin receptor blocker or
             renin inhibitor for at least 30 days

          6. Stable diuretic dose for at least 14 days prior to baseline study Visit

          7. High cardiovascular risk: an age of 50 years or more with at least one cardiovascular
             coexisting condition (coronary heart disease, cerebrovascular disease, peripheral
             vascular disease, chronic kidney disease of stage 3 or greater, or chronic heart
             failure of New York Heart Association class II or III) OR an age of 60 years or more
             with at least one cardiovascular risk factor, as determined by the investigator
             (microalbuminuria or proteinuria, hypertension and left ventricular hypertrophy, left
             ventricular systolic or diastolic dysfunction, or an ankle-brachial index [the ratio
             of the systolic blood pressure at the ankle to the systolic blood pressure in the arm]
             of less than 0.9).

        Exclusion Criteria:

          1. Type 1 Diabetes

          2. Iodine intolerance

          3. Hypersensitivity or allergy to dapagliflozin

          4. Use of an SGLT2 inhibitor within 30 days

          5. Leukocyte and/or nitrite positive urinalysis that is untreated

          6. Severe hypoglycaemia within 1 month prior to screening

          7. Unstable coronary artery disease with acute coronary syndrome, percutaneous
             intervention or bypass surgery within 3 months

          8. Clinically significant valvular disease in the opinion of the investigator

          9. Congestive heart failure secondary to an infiltrative cardiomyopathic process (for
             example amyloid) or pericardial constriction

         10. Bariatric surgery or other surgeries that induce chronic malabsorption within 1 year;

         11. Anti-obesity drugs or diet regimen and unstable body weight three months prior to
             screening;

         12. Treatment with systemic corticosteroids

         13. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells

         14. Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not
             practicing an acceptable method of birth control

         15. Participation in another trial with an investigational drug within 30 days of informed
             consent

         16. Alcohol or drug abuse within three months prior to informed consent that would
             interfere with trial participation or any ongoing clinical condition that would
             jeopardize subject safety or study compliance based on investigator judgement

         17. Liver disease, defined by serum levels of alanine transaminase, aspartate
             transaminase, or alkaline phosphatase &gt;3 x upper limit of normal as determined during
             screening

         18. Medical history of cancer or treatment for cancer in the last five years prior to
             screening, aside from uncomplicated basal cell or squamous cell carcinoma;

         19. Unstable or rapidly progressive renal disease as per investigator judgement

         20. Intolerance or sensitivity to SGLT2 inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vesta Lai, RN</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8508</phone_ext>
    <email>vesta.lai@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuliya Lytvyn, PhD</last_name>
    <email>julia.lytvyn@mail.utoronto.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Renal Physiology Laboratory</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vesta Lai, RN</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>8508</phone_ext>
      <email>vesta.lai@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Yuliya Lytvyn, PhD</last_name>
      <email>julia.lytvyn@mail.utoronto.ca</email>
    </contact_backup>
    <investigator>
      <last_name>David Cherney, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>David Z.I. Cherney</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>SGLT2 inhibition</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Dapagliflozin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

